Tokyo, Sept. 29 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063087) titled 'Risk Factors for Early Recurrent Biliary Obstruction After Multiple Inside Plastic Stent Placement for Unresectable Malignant Hilar Biliary Obstruction: A Multicenter Cohort Study' on Sept. 28.

Study Type: Observational

Primary Sponsor: Institute - First Department of Internal Medicine, Gifu University Hospital

Condition: Condition - Unresectable malignant hilar biliary obstruction Classification by malignancy - Malignancy Genomic information - NO

Objective: Narrative objectives1 - The purpose of this study is to clarify the cumulative incidence and risk factors for early recurrent biliary obstruction (RBO) in patients with unresectable malignant hilar biliary obstruction who underwent ERCP-guided placement of multiple inside plastic stents (iPS). These findings may help optimize the timing of scheduled stent exchanges and strategies for biliary drainage. Basic objectives2 - Safety,Efficacy

Eligibility: Age-lower limit - 18 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - 1. Patients aged 18 years or older 2. Patients who underwent multiple inside plastic stent (iPS) placement at the last planned endoscopic biliary drainage (LPEBD) during the initial planned endoscopic drainage for unresectable malignant hilar biliary obstruction between April 1, 2020 and March 31, 2026 Key exclusion criteria - 1. Patients who declined the use of their clinical information through the opt-out process 2. Patients considered inappropriate for inclusion in the study by the investigators Target Size - 100

Recruitment Status: Recruitment status - Open public recruiting Date of protocol fixation - 2026 Year 06 Month 01 Day Date of IRB - 2026 Year 09 Month 02 Day Anticipated trial start date - 2026 Year 09 Month 02 Day Last follow-up date - 2033 Year 03 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071924

Disclaimer: Curated by HT Syndication.